One-shot gene therapy could deliver long-lasting GLP-1 weight loss

Researchers are pursuing a one-time gene therapy that would program the body to produce GLP-1 hormones endogenously, potentially providing longer-lasting weight loss than current GLP-1 drugs for diabetes and obesity. The Washington Post piece highlights Fractyl Health’s Rejuva program and notes that many patients stop GLP-1 therapies and regain weight, underscoring that the approach is early-stage and faces safety, durability, regulatory, and cost uncertainties.